Cancer News and Research

Latest Cancer News and Research

Orphan drug designation for pixantrone applied by Cell Therapeutics

Cell Therapeutics, Inc. ("CTI") announced today that it has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL.

30 Sep 2009

Hologic's ThinPrep integrated imager receives CE marking approval

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced it has received CE marking approval for its ThinPrep® integrated imager.

From Hologic, Inc. 30 Sep 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

ARRA stimulus funds fuel research projects across America

The Association of American Universities (AAU), the Association of Public and Land-grant Universities (APLU), and The Science Coalition (TSC) today released highlighted examples of the important scientific work happening across the country as a result of the American Recovery and Reinvestment Act of 2009 (ARRA). The brief report summarizes just a handful of the thousands of projects benefiting from stimulus dollars.

30 Sep 2009

Mellow Hope granted H1N1 license by SFDA

The issuer's China based operating subsidiary Mellow Hope through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd has been granted H1N1 license on September 24, 2009 by SFDA (China Authority) http://eng.sfda.gov.cn/eng. Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales.

30 Sep 2009

Topcor launches Clipa for a Cure to support breast cancer research

October is National Breast Cancer Awareness Month and Topcor is introducing a new product to support breast cancer research.

30 Sep 2009

Oilfield leader builds unique colored rig to support breast cancer research

If you're seeing pink where you wouldn't normally expect in the Western states, you're not color blind. A Colorado-based company has built the Pink Rig, a hydraulic workover unit with snubbing capabilities that is literally painted pink.

30 Sep 2009

NuGEN launches the Ovation WGA System for genome amplification

NuGEN Technologies Inc, a pace-setter in nucleic acid sample preparation, announces its entrance into the DNA market today with the Ovation WGA System, a linear, remarkably reliable, and more robust solution to whole genome amplification.

30 Sep 2009

Non-human primate study results of Restanza released

Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.

30 Sep 2009

Urodynamix: Cross of 1,480,000 common shares effected through Canaccord Capital

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share.

30 Sep 2009

Study shows that exposure to radon gas leads to lung cancer

Exposure to radon gas in homes is the second leading cause of lung cancer after smoking, according to a study carried out by researchers from the University of Cantabria and the Babes-Bolyai University in Romania. The team has studied data on exposure to this element in a uranium mining area in Transylvania and in an area of granite in Torrelodones, Madrid

30 Sep 2009

Researchers identify embryonic origin of Merkel cells

Publication in Journal of Cell Biology : researchers from ULB (IRIBHM) identify the embryonic origin of Merkel cells. Their research continue on an extremely aggressive cancer, the Merkel cell carcinoma

30 Sep 2009

SATAI invests $1.045 million in Azaya Therapeutics

SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya’s proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Coupling electrosurgery with mass spectrometry for real-time identification of tumor tissues

Instead of the classic scalpel, surgeons can also operate with an electroscalpel. A significant advantage to this technique is that while a cut is being made, blood vessels are closed off and hemorrhaging eliminated. Now another advantage may be added as well: a German-Hungarian research team has developed a mass-spectrometry-based technique by which tissues can be analyzed during a surgical procedure.

30 Sep 2009

New research may enhance the treatment for blood cancer in children

Acute lymphatic leukemia is the most common form of blood cancer in children. Even though chemotherapy is improving, the cancer often returns. Johan Jansson's research at Kalmar University in Sweden shows that cancer cells that have been exposed to chemotherapy and survived are less vulnerable to chemotherapy, and more aggressive as well. But this research also yielded discoveries that should be able to enhance our treatment of the disease.

30 Sep 2009

Mater Health Services implements Cisco Medical-Grade Network to improve health care

Cisco announced today that Mater Health Services, Queensland's largest not-for-profit hospital group, is making significant strides in achieving its Smart Hospital strategy with a roll-out of an expanded suite of business applications on its Cisco® Medical-Grade Network across its seven ultra-modern hospitals.

30 Sep 2009

Overweight middle-age women could reduce their chances of enjoying a healthy old age: Study

Women who put on weight as they approach middle-age could reduce their chances of enjoying a healthy old age by up to 80%, according to research from the University of Warwick.

30 Sep 2009

Burzynski Research Institute and BBSF sign Research Agreement

The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management support for BRI’s ongoing Phase II and Phase III protocol studies of Antineoplaston (ANP) treatment for gliomas.

30 Sep 2009

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.

30 Sep 2009